ArticleBMC neurology2026

Real-world effectiveness of onabotulinumtoxinA as first-line treatment in chronic migraine and sequential transition to anti-CGRP monoclonal antibodies: a retrospective multicenter study.

Katarzyna Kępczyńska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.